The new study indicating that the treatment with the prasugrel (an antiplatelet agent) does not significantly reduce the rate of pain crises or severe lung complications in children with sickle cell disease, has been published in the New England Journal of Medicine. Sickle cell disease affects around 100 million children around the globe. The prevalence of sickle cell disease is found in a sub-Saharan region, Middle East and India. The disease is a genetic disease and has a multidimensional pathophysiology.
Prasugrel is an antiplatelet agent or platelet inhibitor, which prevents platelets from aggregating by blocking the enzyme called P2Y12. The oral drug is also approved for cardiac patients to reduce the risk of clots following angioplasty or insertion of an arterial stent. To check whether prasugrel can be used as a medication for reducing the rate of vaco-occlusive crises (VOCs).…
